China Study Finds Cilostazol Better Than Aspirin After Stroke
This article was originally published in PharmAsia News
Executive Summary
Chinese researchers have determined cilostazol, an anti-clotting drug, may be safer than aspirin for some people who have had a stroke. Such patients are considered at higher risk of a cerebral hemorrhage, but the anti-platelet drug appears to have a long-term effect in low doses. The researchers' work was published online by the journal The Lancet Neurology. Cilostazol is made in China by Otsuka Pharmaceutical under the brand Pletal. (Click here for more
You may also be interested in...
Otsuka Signs On To Promote Two UCB Products Just In Time For Possible Raised Safety Concerns
Otsuka and UCB have agreed to a co-development and co-promotional deal for the Belgium firm's antiepileptic Keppra (levetiracetam) and anti-TNF alpha drug Cimzia (certolizumab pegol) for the Japanese market while both products currently face potential safety hurdles in the U.S
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.